Macrolides vs no intervention
Serious adverse events ‐ not reported · adults with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
44 questions · 44 findings · 17 reviews
No studies found 10 · 22.7%GRADE not reported 4 · 9.1%Very low 16 · 36.4%Low 9 · 20.5%Moderate 4 · 9.1%High 1 · 2.3%
Azithromycin vs placebo or usual care
Serious adverse events during the study period · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review
- no estimate extracted2 studies · 454 participantsVery low
Azithromycin vs placebo or usual care
Serious adverse events during the study period · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in serious adverse events during the study period compared with placebo or standard of care alone (moderate certainty).
1 finding from 1 review
- RR 1.11 [0.89, 1.4]4 studies · 794 participantsModerate
Oral + inhaled dual therapy vs oral monotherapy
Serious adverse events. Outcome assessed on day 42 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes serious adverse events. Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
1 finding from 1 review
- OR 0.48 [0.08, 2.87]1 study · 53 participantsVery low